Clinical Trial Update: Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial of immunotherapy using tumor-infiltrating lymphocytes for metastatic melanoma has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Tumor-infiltrating lymphocytes (TIL) therapy

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Melanoma, Skin Cancer | Phase 2 | Status: TERMINATED | Results posted: 2016-06-27